10.11.16
9:40 a.m. – 12:00 p.m., Nov 16, Four Seasons Ballroom 2/3
Speakers: John Carpenter, Ph.D., Professor of Pharmaceutical Sciences, University of Colorado; Kenneth Dawson, Ph.D., Director Center for Bionano Intertactions, University College Dublin; Amber Fradkin, Ph.D., Associate Director, KBI Biopharma, Inc.; Stephan Stern, Ph.D., Principal Scientist, NCL, Frederick National Laboratory for Cancer Research
The rise of nanotechnology has led to the development of nonbiological complex drug products (NBCDs). For this symposium, we will discuss a series of recent progress in analytical techniques to characterize these nanomedicines/NBCD products in detail and to understand what characteristics are crucial to their performance as a formulated product and/or in clinical testing. This will stimulate science-based discussion between scientists, drug developers (of novel nanomedicines and follow-on versions), regulators, and other stakeholders to further our thinking on these challenging issues.
Speakers: John Carpenter, Ph.D., Professor of Pharmaceutical Sciences, University of Colorado; Kenneth Dawson, Ph.D., Director Center for Bionano Intertactions, University College Dublin; Amber Fradkin, Ph.D., Associate Director, KBI Biopharma, Inc.; Stephan Stern, Ph.D., Principal Scientist, NCL, Frederick National Laboratory for Cancer Research
The rise of nanotechnology has led to the development of nonbiological complex drug products (NBCDs). For this symposium, we will discuss a series of recent progress in analytical techniques to characterize these nanomedicines/NBCD products in detail and to understand what characteristics are crucial to their performance as a formulated product and/or in clinical testing. This will stimulate science-based discussion between scientists, drug developers (of novel nanomedicines and follow-on versions), regulators, and other stakeholders to further our thinking on these challenging issues.